Nogenic diabetes: implications for therapy of uncommon varieties of illness. Diabetes Obes Metab 2008;10:60716 111. Nordin C. The case for hypoglycaemia as a proarrhythmic occasion: simple and clinical proof. Diabetologia 2010;53: 1552561 112. Riveline JP, Danchin N, Ledru F, Varroud-Vial M, Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Obtainable data in humans and clinical applications. Diabetes Metab 2003;29:20722 113. Sulistio M, Carothers C, Mangat M, Lujan M, Oliveros R, Chilton R. GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with possible cardioprotective effects. Curr Atheroscler Rep 2009;11:939 Hanefeld M, Schaper F. Acarbose: oral anti-diabetes drug with added cardiovascular positive aspects. Expert Rev Cardiovasc Ther 2008;6:15363 Gaziano JM, Cincotta AH, O’Connor CM, et al.Amlodipine Randomized clinical trial of quickrelease bromocriptine among individuals with kind 2 diabetes on all round security and cardiovascular outcomes.Proteinase K Diabetes Care 2010;33:1503508 Masoudi FA, Inzucchi SE.PMID:23008002 Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 2007;99:113B32B Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and sort two diabetes offered thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129136 Chaggar PS, Shaw SM, Williams SG. Critique write-up: Thiazolidinediones and heart failure. Diab Vasc Dis Res 2009;6: 14652 Tahrani AA, Varughese GI, Scarpello JH, Hanna FW. Metformin, heart failure, and lactic acidosis: is metformin certainly contraindicated BMJ 2007;335:50812 Inzucchi SE, McGuire DK. New drugs for the remedy of diabetes: component II: Incretin-based therapy and beyond. Circulation 2008;117:57484 Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic manage, complications, and death in older diabetic sufferers: the Diabetes and Aging Study. Diabetes Care 2011;34:1329336 Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney illness amongst sufferers with sort 2 diabetes mellitus within the United states. Clin Ther 2009;31:2608617 Holstein A, Stumvoll M. Contraindications can damage your healthdis metformin a case in point Diabetologia 2005;48: 2454459 Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin within the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011; 34:1431437 Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney illness Nephron Clin Pract 2011;118:c380 383 Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007;11:16, vii Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver illness (NAFLD) and diagnostic accuracy of non-invasive tests for liver illness severity. Ann Med 2011;43:61749 Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006;26:1015017 Gerstein HC, Miller ME, Genuth S, et al.; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:81828 Bonds DE, Miller ME, Bergenstal RM, et al. The association amongst symptomatic, severe hypoglycaemia and mortality in sort two diabetes: retrospective epidemiological analysis from the ACCORD study. BMJ 2010;340:b4909 Riddle MC. Counterpoint: Intensive glucose handle and mor.
